Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | TLR2 | O60603 | 1/20 | 0.46 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | CXCR5 | P32302 | 1/20 | 0.41 |
| ▸ | APLNR | P35414 | 1/20 | 0.41 |
| ▸ | CCR6 | P51684 | 1/20 | 0.41 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.40 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1773066 | 0.87 | ALDH1A1 (0.46) | MAPTALDH1A1TRPV1NPSR1GAA | |
| SCHEMBL10847396 | 0.83 | MAPT (0.44) | MAPTALDH1A1NPSR1ABCC8KCNJ11 | |
| SCHEMBL2404162 | 0.81 | ALDH1A1 (0.53) | MAPTALDH1A1GAAHTTTSHR | |
| SCHEMBL2655580 | 0.78 | ALDH1A1 (0.44) | MAPTTLR2TLR1ALDH1A1TSHR | |
| SCHEMBL1663659 | 0.76 | ALDH1A1 (0.54) | MAPTALDH1A1NPSR1HSP90AA1CXCR5 | |
| SCHEMBL30509934 | 0.75 | ABCC8 (0.42) | MAPTTLR2TLR1ALDH1A1NPSR1 | |
| SCHEMBL18448340 | 0.75 | MAPT (0.53) | MAPTTLR2TLR1ALDH1A1TRPV1 | |
| SCHEMBL1765224 | 0.75 | KIF11 (0.47) | ALDH1A1TRPV1KDM4EMAPK1 | |
| SCHEMBL1765772 | 0.75 | KIF11 (0.47) | ALDH1A1TRPV1KDM4E | |
| SCHEMBL2402918 | 0.75 | DHODH (0.48) | MAPTALDH1A1NPSR1GAAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150266861-A1 | Glucagon Receptor Modulators | PFIZER INC. (US) | 2015-09-24 | — | — | US | disclosed |
| US-20150266861-A1 | Glucagon Receptor Modulators | PFIZER INC. (US) | 2015-09-24 | — | — | US | disclosed |
| US-20150266861-A1 | Glucagon Receptor Modulators | PFIZER INC. (US) | 2015-09-24 | — | — | US | disclosed |
| CN-103261165-B | Glucagon receptor modulators | PFIZER INC. (US) | 2015-08-26 | — | — | CN | disclosed |
| US-9056834-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2015-06-16 | — | — | US | disclosed |
| US-9056834-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2015-06-16 | — | — | US | disclosed |
| US-9056834-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2015-06-16 | — | — | US | disclosed |
| US-20150094338-A1 | Glucagon Receptor Modulators | PFIZER INC. (US) | 2015-04-02 | — | — | US | disclosed |
| US-20150094338-A1 | Glucagon Receptor Modulators | PFIZER INC. (US) | 2015-04-02 | — | — | US | disclosed |
| US-20150094338-A1 | Glucagon Receptor Modulators | PFIZER INC. (US) | 2015-04-02 | — | — | US | disclosed |
| CN-1968921-B | Glucagon receptor antagonists, preparation and therapeutic uses | LILLY CO ELI | 2011-11-23 | — | — | CN | disclosed |
| US-20110124648-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2011-05-26 | — | — | US | disclosed |
| US-20100324140-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2010-12-23 | — | — | US | disclosed |
| US-7816557-B2 | 3-{4-[1-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-yloxy)-4,4,4-trifluoro-butyl]-benzoylamino}-propionic acid; treat diabetic and other glucagon related metabolic disorders | ELI LILLY AND COMPANY (US) | 2010-10-19 | — | — | US | disclosed |
| EP-2159221-A1 | Glucagon receptor antagonists, preparation and therapeutic uses | Eli Lilly & Company (US) | 2010-03-03 | — | — | EP | disclosed |
| EP-1758853-B1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2010-01-20 | — | — | EP | disclosed |
| US-20070249688-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | ELI LILLY AND COMPANY (US) | 2007-10-25 | — | — | US | disclosed |
| CN-1968921-A | Glucagon receptor antagonists, preparation and therapeutic uses | LILLY CO ELI (US) | 2007-05-23 | — | — | CN | disclosed |
| EP-1758853-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005123668-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124648-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | GLP1R, GCGR, GIPR | MAPT 4737/4885TLR2 1181/4885TLR1 1457/4885 |
| US-20070249688-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | GLP1R, GCGR, GIPR | MAPT 4737/4885TLR2 1181/4885TLR1 1457/4885 |
| US-20150094338-A1 | Glucagon Receptor Modulators | GLP1R, GCGR, GPR119 | MAPT 4254/4885TLR2 740/4885TLR1 576/4885 |
| US-20100324140-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | GLP1R, GCGR, GIPR | MAPT 4737/4885TLR2 1181/4885TLR1 1457/4885 |
| US-20150266861-A1 | Glucagon Receptor Modulators | GLP1R, GCGR, GPR119 | MAPT 4254/4885TLR2 740/4885TLR1 576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.